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Positron emission tomography (PET) has a growing use
in medical decision making and management of patients. To
further apply the unique properties of PET, more clinically
validated PET-radiopharmaceuticals are required and
subsequently new and better radiochemical preparation
methods are under development stimulates the use of different
radiometals as 68Ga, 89Zr and 64Cu for clinical use.
Depending on the biological target of interest and the
properties of the PET-radiopharmaceutical the proper
radionuclide should be selected.
For the treatment and diagnosis of malignancies, various
radiolabeled monoclonal antibodies have also been
developed. Rituximab selectively binds with high affinity to the
CD20 antigen (human B-lymphocyte restricted differentiation
antigen, Bp35), which is expressed on B-lymphocytes and on
>90 % of B cell non-Hodgkin lymphomas (NHL). These
properties make the CD20 receptor a suitable target for
radiotherapy/diagnostic purposes.
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Rituximab, conjugated with three different BFCA’s,
 p-SCN-Bn-DOTA, 
(2-(4-izothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid)
 p-SCN-Bn-DTPA
(2-(4-izothiocyanatobenzyl)-diethylenetriaminepentaacetic acid)
and
 1B4M-DTPA
(2-(4-izothiocyanatobenzyl)-6-methyl-diethylenetriaminepentaacetic
acid)
in a form of freeze-dried preparation, was subjected to
characterization and determination of secondary structure,
quality parameters (purity, integrity, fragmentation and
aggregation of the antibody), and average number of BFCA’s
attached with employment of different analytical techniques
such as:
 Matrix-Assisted Laser Desorption Ionization Time-of-Flight 
Mass Spectrometry (MALDI-TOF-MS), 
 Sodium Dodecyl Sulphate-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE),
 Fourier Transform Infrared (FT-IR) and 
 Raman Spectroscopy.
After lyophilisation, diluted rituximab immunoconjugates remain
stable. No modification of its physico-chemical characteristics,
no aggregation, and preservation of antibody secondary
structure were observed.
 The time frame for the practical use of rituximab
immunoconjugates can be safely extended using lyophilisation,
enabling, for example, safe and longer storage and supporting
the possibility of developing a “ready-to-label” rituximab
immunoconjugates for imaging/therapy.
 Further experiments are still needed in order to demonstrate
biological and pharmacological properties.
Development of 68Ga-labeled rituximab immunoconjugates
(in a form of lyophilised formulation) may provide PET
screening of the therapeutic outcomes following 177Lu therapy.
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Fig.1: MALDI-TOF results for three 
BFCA-rituximab conjugates: 
1: p-SCN-Bn-DOTA; (binding of 6.1 
groups)
2: p-SCN-Bn-DTPA (binding of 8.8 
groups) and 
3: 1B4M-DTPA (binding of 8.3 groups)
Fig. 2: Reducing 
SDS-PAGE lane 
patterns of 
rituximab (1), 
p-SCN-Bn-DOTA-
rituximab (2), 
p-SCN-Bn-DTPA-
rituximab (3), 1B4M-
DTPA-rituximab (4).
Fig. 3: Raman and ATR-IR spectra of rituximab
and three types of experimental conjugates. 
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Schematic process of conjugation and labeling of three BFCA*-rituximab conjugates.
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